Losartan Potassium Tablet, Film Coated
Product Images NDC 55154-6643

8 FDA label images from Cardinal Health 107, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 55154-6643). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Structure)

Structural Formula (Structure)
Chemical structure diagram of the active ingredient Losartan Potassium, showing its molecular components including chlorine, nitrogen-containing rings, and a potassium ion.*
FDA Label Image

Figure 1: Kaplan-meier Estimates Of The Primary Endpoint Of Time To Cardiovascular Death, Nonfatal Stroke, Or Nonfatal Myocardial Infarction In The Groups Treated With Losartan Potassium And Atenolol. (Figure1)

Figure 1: Kaplan-meier Estimates Of The Primary Endpoint Of Time To Cardiovascular Death, Nonfatal Stroke, Or Nonfatal Myocardial Infarction In The Groups Treated With Losartan Potassium And Atenolol. (Figure1)
A line graph comparing the percentage of patients with the primary endpoint over study months 0 to 66 for Losartan Potassium and Atenolol. The graph shows cumulative percentages on the y-axis, with Losartan Potassium represented by a solid line and Atenolol by a dashed line. The chart includes an adjusted risk reduction of 13% with a p-value of 0.021.*
FDA Label Image

Figure 2: Kaplan-meier Estimates Of The Time To Fatal/nonfatal Stroke In The Groups Treated With Losartan Potassium And Atenolol. (Figure2)

Figure 2: Kaplan-meier Estimates Of The Time To Fatal/nonfatal Stroke In The Groups Treated With Losartan Potassium And Atenolol. (Figure2)
A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months between Atenolol (dashed line) and Losartan Potassium (solid line). The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of patients from 0 to 8%. The graph indicates an adjusted risk reduction of 25% for Losartan Potassium with a p-value of 0.001.*
FDA Label Image

Figure 3: Primary Endpoint Events† Within Demographic Subgroups (Figure 3)

Figure 3: Primary Endpoint Events† Within Demographic Subgroups (Figure 3)
A forest plot comparing Losartan Potassium and Atenolol event rates for primary composite and stroke (fatal/non-fatal) outcomes across different patient subgroups, including age, gender, race, ischemic heart disease (ISH), diabetes, and history of cardiovascular disease (CVD). The plot displays hazard ratios with 95% confidence intervals, illustrating the relative effectiveness of Losartan Potassium versus Atenolol in these categories.*
FDA Label Image

Figure 4: Kaplan-meier Curve For The Primary Composite Endpoint Of Doubling Of Serum Creatinine, End Stage Renal Disease (need For Dialysis Or Transplantation) Or Death. (Figure4)

Figure 4: Kaplan-meier Curve For The Primary Composite Endpoint Of Doubling Of Serum Creatinine, End Stage Renal Disease (need For Dialysis Or Transplantation) Or Death. (Figure4)
A line graph comparing percentage of patients with events over 48 months between Losartan Potassium Tablet and placebo groups. The x-axis shows months (0 to 48), and the y-axis shows percent of patients with event (0% to 60%). The graph indicates a risk reduction of 16.1% with a p-value of 0.022.*
FDA Label Image

25mg Bag Label (550314c5 433f 4e48 E063 6394a90a920e 02)

25mg Bag Label (550314c5 433f 4e48 E063 6394a90a920e 02)
Losartan Potassium Tablets USP 25 mg film-coated oral tablets packaging label showing a 10-tablet unit dose. The label includes storage instructions (20° to 25°C, excursions allowed between 15° to 30°C), a warning that the package is not child resistant, and distribution information for American Health Packaging and Cardinal Health.*
FDA Label Image

50mg Bag Label (550314c5 433f 4e48 E063 6394a90a920e 01)

50mg Bag Label (550314c5 433f 4e48 E063 6394a90a920e 01)
Losartan Potassium Tablets, USP 50 mg film-coated tablets packaging label. The package contains 10 tablets and states storage instructions, warnings, and distribution information. Labeler is Cardinal Health 107, LLC, with distribution also by American Health Packaging in Columbus, OH. Text includes dosage strength and instructions for handling and protection.*
FDA Label Image

100mg Bag Label (550314c5 433f 4e48 E063 6394a90a920e 00)

100mg Bag Label (550314c5 433f 4e48 E063 6394a90a920e 00)
Losartan Potassium 100 mg tablets label. The image shows a white label for a 10-tablet package of Losartan Potassium film-coated tablets, USP, 100 mg strength. The label includes storage instructions, warnings that the package is not child resistant and intended for institutional use only, and distributor information listing Cardinal Health and American Health Packaging.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.